Erythromycin increases the maximum
plasma level and AUC of
cilostazol by 47% and 73%, respectively. Other drugs that inhibit CYP3A4 (e.g. the
protease inhibitors) would be expected to have a similar effect.
In view of these effects the US manufacturers suggest halving the dose of
cilostazol in the presence of CYP3A4 inhibitors such as
erythromycin. However, the UK manufacturers contraindicate CYP3A4 inhibitors, and they specifically name the
protease inhibitors.